Scotiabank raised the firm’s price target on Twist Bioscience to $43 from $30 and keeps an Outperform rating on the shares. The company beat expectations on the top line and also gross margins in fiscal Q1, the analyst tells investors in a research note. The firm says the full year revenue guidance was raised by roughly the Q1 beat, which reflects management’s conservatism.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TWST:
- Twist Bioscience price target raised to $25 from $19 at JPMorgan
- Twist Bioscience sees Q2 revenue $70M-$71M, consensus $70.09M
- Twist Bioscience raises FY24 revenue view to $288M-$293M from $285M-$290M
- Twist Bioscience reports Q1 EPS (75c), consensus (78c)
- Options Volatility and Implied Earnings Moves Today, February 02, 2024
